



2023 3 17

2023 020048

2023

A

2023

A

| | |
|---------------|------------|
| 1..... | 3 |
| 2..... | 37 |
| 3..... | 89 |
| 4..... | 96 |
| | 104 |

2021

8

9

1 2 5 6

| | 2022 | 1-9 | 2021 | 2020 | 2019 |
|--|-----------|-----|-----------|-----------|-----------|
| | 29,746.65 | | 37,044.22 | 36,848.94 | 41,486.63 |
| | 12,482.36 | | 13,834.55 | 12,467.84 | 9,339.80 |
| | 17,264.29 | | 23,209.67 | 24,381.10 | 32,146.83 |
| | 58.04% | | 62.65% | 66.16% | 77.49% |
| | 31,472.19 | | 30,890.45 | 24,587.01 | 31,818.02 |
| | 12,014.95 | | 6,898.95 | 4,747.18 | 5,321.34 |
| | -8,730.26 | | -4,448.34 | 1,516.14 | 1,254.69 |
| | -8,163.72 | | -3,416.40 | 1,652.86 | 1,258.49 |
| | 434.00 | | 1,118.97 | 1,335.36 | 1,427.61 |
| | -7,583.31 | | -4,607.63 | 147.09 | -353.42 |
| | | | 41,486.63 | 36,848.94 | 37,044.22 |

| | | | | | | |
|--------|-----------|-----------|------|------|-----|---------|
| | 29,746.65 | | | | | -353.42 |
| 147.09 | -4,607.63 | -7,583.31 | 2021 | 2022 | 1-9 | |

1

IPO
2016

| | | | | | | |
|----------|-----------|----------|------|----------|--------|----------|
| | | | | | | I |
| II | | | | | | 2020 |
| | 2021 | 2022 | 1-9 | | | |
| | | | | 4,747.18 | | 6,898.95 |
| | 12,014.95 | | | 12.88% | 18.62% | 40.39% |
| 2021 | | | | | | |
| | | | | | | 3,043.96 |
| 3,952.99 | | 9,030.98 | | | | 2021 |
| | | | 2022 | 1-9 | | |

| | 2022 | 1-9 | 2021 | 2020 |
|---------|------|-----------|-----------|----------|
| | | -7,583.31 | -4,607.63 | 147.09 |
| | | 9,030.98 | 3,952.99 | 3,043.96 |
| +6 | | 1,447.68 | -654.63 | 3,191.05 |
| 2021 11 | | | 2021 11 | |

2

2021 2022 1-9

| | | | | | | | |
|------|-----------|------|-----------|------|-----------|-----|------|
| | | | 2020 | 2021 | 2022 | 1-9 | |
| | 24,381.10 | | 23,209.67 | | 17,264.29 | | |
| 2020 | 2021 | 2022 | 1-9 | | | | 0.63 |
| / | 0.48 | / | 0.41 | / | | | |

2019 9 2020 1

| | 2022 1-9 | 2021 | 2020 | 2019 |
|--|------------------|------------------|------------------|------------------|
| | 34,666.80 | 54,213.70 | 52,864.08 | 53,505.95 |
| | 54,357.99 | 67,047.77 | 79,410.08 | 89,267.06 |
| | 36,232.58 | 94,487.10 | 109,498.40 | 78,183.75 |
| | 22,535.68 | -47,160.21 | 32,806.76 | 43,479.64 |
| | 10,416.74 | 14,954.79 | 8,352.77 | 18,089.03 |
| | 36,810.10 | 29,679.31 | 21,574.26 | 14,441.83 |
| | 32,503.32 | 35,537.08 | 50,751.06 | 49,494.54 |
| | 3,149.39 | 2,329.83 | 6,282.14 | 6,536.29 |

Wind

2021

13,264.91 44.59%

| | | 2022 1-9 | | 2021 | | 2020 | | 2019 |
|--|---|-----------|---------|-----------|---------|-----------|---------|----------|
| | | / | / | / | / | / | / | / |
| | | 29,080.90 | 8.31% | 34,737.24 | 6.15% | 32,725.28 | 288.27% | 8,428.48 |
| | | 0.41 | -14.58% | 0.48 | -23.81% | 0.63 | -79.41% | 3.06 |
| | | 0.23 | -4.17% | 0.24 | -4.00% | 0.25 | -56.90% | 0.58 |
| | % | 43.14 | 7.92 | 51.06 | 9.20 | 60.26 | 20.88 | 81.14 |

2022 1-9
2021

2021 1-9

| | 2022 1-9 2021 | 2021 2020 | 2020 2019 |
|--|------------------|-----------|-----------|
| | -7.92 | -9.20 | -20.88 |
| | -9.38 | -11.69 | -73.33 |
| | 1.46 | 2.49 | 52.45 |

= / - /
= / - /

2019 9 2020 1

2020 2019
1.50% 37.32% 2021 2022 1-9
47.79% 49.38%

2020

2

79.35%

79.83% 80.55% 80.04%

1

| | % | | | |
|--|--------------|--------------|--------------|--------------|
| | 2022 1-9 | 2021 | 2020 | 2019 |
| | 43.95 | 44.53 | 44.01 | 45.57 |
| | 56.52 | 55.46 | 57.24 | 57.43 |
| | 67.87 | 65.98 | 68.07 | 65.76 |
| | 59.76 | 62.85 | 65.40 | 63.74 |
| | 81.08 | 80.90 | 81.74 | 87.77 |
| | 89.33 | 88.95 | 89.46 | 89.04 |
| | 66.42 | 66.44 | 67.65 | 68.22 |
| | 58.04 | 62.65 | 66.17 | 77.49 |

Wind

A23037.SH

IPO

| | | | 2022 1-9 / 2022 1-6 | 2021 | 2020 | 2019 |
|---|----------|--------|--------------------------------|-------------|-------------|-------------|
| | | | 4,525.13 | 11,330.45 | 13,435.61 | 31,765.40 |
| | | % | 77.29 | 74.99 | 72.80 | 85.39 |
| | | | 5,981.11 | 8,781.39 | 12,854.36 | 25,429.62 |
| | - | % | 66.53 | 73.02 | 77.68 | 82.51 |
| | | | 5,834.43 | 8,038.71 | 7,653.26 | 388.00 |
| | - | % | 19.16 | 27.07 | 31.00 | -8.66 |
| 1 | 2022 1-6 | 2 2019 | | | - | -8.66% |

1

| | 2022 | 1-9 | 2021 | | 2020 | | 2019 | |
|--|------------------|-------------|------------------|-------------|------------------|-------------|------------------|-------------|
| | | | | | | | | |
| | 9,377.30 | 71.01% | 12,206.58 | 71.89% | 10,780.92 | 74.50% | 16,441.94 | 77.79% |
| | 3,260.16 | 24.69% | 3,909.39 | 23.02% | 3,046.88 | 21.05% | 3,477.61 | 16.45% |
| | 277.97 | 2.11% | 396.58 | 2.34% | 213.36 | 1.47% | 425.08 | 2.01% |
| | 180.22 | 1.36% | 220.16 | 1.30% | 194.52 | 1.34% | 243.90 | 1.15% |
| | 42.45 | 0.32% | 88.22 | 0.52% | 77.27 | 0.53% | 119.40 | 0.56% |
| | 56.46 | 0.43% | 123.52 | 0.73% | 95.53 | 0.66% | 100.68 | 0.48% |
| | 4.61 | 0.03% | 16.28 | 0.10% | 50.54 | 0.35% | 56.28 | 0.27% |
| | 5.53 | 0.04% | 18.24 | 0.11% | 12.41 | 0.09% | 270.20 | 1.28% |
| | 13,204.69 | 100% | 16,978.96 | 100% | 14,471.44 | 100% | 21,135.08 | 100% |

94%

2

1

| | 2022 1-9 | 2021 | 2020 | 2019 |
|--|-----------------|-------------|-------------|-------------|
| | 13,204.69 | 16,978.96 | 14,471.44 | 21,135.08 |
| | 29,746.65 | 37,044.22 | 36,848.94 | 41,486.63 |
| | 7,322.95 | 8,492.51 | 7,653.26 | 388.00 |
| | 24.62% | 22.93% | 20.77% | 0.94% |
| | 44.39% | 45.83% | 39.27% | 50.94% |

2020 2019 6,663.64
50.94% 39.27%
2019 9 2020 1 2020
2019 0.94%
20.77%

2021 2020 2,507.52

1

18.73%

2

2022 1-9 2021

2

| | 2022 1-9 | 2021 | 2020 | 2019 |
|--|-----------------|-------------|-------------|-------------|
| | 3,232.50 | 4,663.74 | 4,824.86 | 11,912.77 |

| | | 2022 1-9 | 2021 | 2020 | 2019 |
|--|--|-----------------|-------------|-------------|-------------|
| | | 11,815.53 | 16,820.10 | 20,507.61 | 25,817.62 |
| | | 27.36% | 27.73% | 23.53% | 46.14% |
| | | 7,683.53 | 9,369.78 | 7,820.63 | 7,025.38 |
| | | 13,264.91 | 16,290.40 | 13,720.38 | 13,048.61 |
| | | 57.92% | 57.52% | 57.00% | 53.84% |

2020

1

2

2020

2021

2022 1-9

| | | | | |
|-----------|----------|----------|----------|--------|
| | 5,321.34 | 4,747.18 | 6,898.95 | |
| 12,014.95 | 12.83% | 12.88% | 18.62% | 40.39% |

| | | | | 2022 9 30 |
|-----------|-----------|------------------|--------|-----------|
| | | | | |
| 3CL | GST-HG171 | 5,685.38 | - | I |
| | 1 | | | Ib |
| GST-HG141 | | 4,935.93 | - | II |
| | C-Met 1 | | | |
| GST-HG161 | | 4,129.95 | - | I |
| | 1 | | | |
| GST-HG131 | | 2,954.82 | - | I |
| | 1 | | | |
| GST-HG121 | | 2,508.75 | - | I |
| | 1 ASK1 | | | |
| 1 | GST-HG151 | 821.06 | - | I |
| | | 21,035.89 | - | - |
| | 3 +3 | | | |
| | | 1,231.96 | 920.12 | |

1,053.91

-

BE



| | | | | | |
|-----------|-----|----------|-----------|-----------|----------|
| | | | | | CRO |
| | | | | | CRO |
| 2022 | 1-9 | | 2021 | | 6,350.84 |
| | | | 1 | GST-HG171 | 2021 |
| 2022 | 1-9 | | | | |
| | | | 2022 | 9 | |
| | | 5,389.21 | | 2 | |
| | | | | | |
| | | | GST-HG171 | | 2022 4 |
| | | | 2022 | 1-9 | |
| | | | 1,053.91 | 2022 | 12 |
| | | | | | |
| | | | | | CRO |
| | | | | | |
| | | | 2022 | 1-9 | |
| GST-HG171 | | | | | |

| | 2022 1-9 | | 2021 | | 2020 | | 2019 | |
|--|------------------|-------------|------------------|-------------|------------------|-------------|------------------|-------------|
| | | | | | | | | |
| | 11,815.53 | 39.72% | 16,820.10 | 45.41% | 20,507.61 | 55.65% | 25,817.62 | 62.23% |
| | 13,264.91 | 44.59% | 16,290.40 | 43.98% | 13,720.38 | 37.23% | 13,048.61 | 31.45% |
| | 1,388.35 | 4.67% | 1,970.08 | 5.32% | 2,044.12 | 5.55% | 1,870.23 | 4.51% |
| | 227.50 | 0.76% | 477.28 | 1.29% | 438.44 | 1.19% | 621.47 | 1.50% |
| | 1,609.29 | 5.41% | 544.08 | 1.47% | -0.03 | 0.00% | 28.66 | 0.07% |
| | 391.55 | 1.32% | 871.23 | 2.35% | - | - | - | - |
| | 1,049.51 | 3.53% | 71.05 | 0.19% | 138.42 | 0.38% | 100.04 | 0.24% |
| | 29,746.65 | 100% | 37,044.22 | 100% | 36,848.94 | 100% | 41,486.63 | 100% |

1

2015

2019 10


2

2020

| | | 2020 | 2021 |
|------|----------|----------|----------|
| 2022 | 1-9 | 1,224.38 | 2,653.51 |
| | 5,606.93 | | |

27

3



| | 2022.9.30 | | | 2021.12.31 | | |
|--|-----------------|---------------|-----------------|-----------------|---------------|-----------------|
| | | | | | | |
| | 1,498.71 | 10.16 | 1,488.56 | 1,170.33 | 13.85 | 1,156.48 |
| | 1,561.54 | - | 1,561.54 | 2,454.19 | - | 2,454.19 |
| | 877.36 | - | 877.36 | 1,180.32 | - | 1,180.32 |
| | 1,909.65 | 91.49 | 1,818.15 | 2,305.35 | 174.07 | 2,131.28 |
| | 172.93 | - | 172.93 | 168.13 | - | 168.13 |
| | 994.47 | - | 994.47 | 983.16 | - | 983.16 |
| | 12.98 | - | 12.98 | 1.91 | - | 1.91 |
| | 323.96 | - | 323.96 | 104.1 | - | 104.10 |
| | 7,351.59 | 101.65 | 7,249.94 | 8,367.48 | 187.92 | 8,179.57 |
| | 2020.12.31 | | | 2019.12.31 | | |
| | | | | | | |
| | 1,004.43 | 4.86 | 999.57 | 465.82 | - | 465.82 |
| | 915.52 | - | 915.52 | 230.41 | 15.74 | 214.67 |
| | 1,270.79 | - | 1,270.79 | 871.75 | - | 871.75 |
| | 1,415.23 | 5.01 | 1,410.22 | 1,493.79 | 9.73 | 1,484.06 |
| | 32.75 | - | 32.75 | 17.85 | - | 17.85 |
| | 458.66 | 3.39 | 455.27 | 427.82 | 0.56 | 427.26 |
| | 181.35 | - | 181.35 | 49.74 | - | 49.74 |
| | 5.64 | 0.48 | 5.17 | 13.22 | - | 13.22 |
| | 5,284.38 | 13.74 | 5,270.64 | 3,570.39 | 26.02 | 3,544.36 |

| | 2022.9.30 | | 2021.12.31 | | 2020.12.31 | | 2019.12.31 | |
|---|-----------|--------|------------|--------|------------|--------|------------|--------|
| | | | | | | | | |
| 1 | 7,146.61 | 97.21% | 8,099.31 | 96.79% | 5,151.04 | 97.47% | 3,364.86 | 94.25% |

| | 2022.9.30 | 2021.12.31 | 2020.12.31 | 2019.12.31 |
|--|-----------------|-----------------|-----------------|-----------------|
| | 1,909.65 | 2,305.35 | 1,415.23 | 1,493.79 |
| | 172.93 | 168.13 | 32.75 | 17.85 |
| | 2,082.57 | 2,473.48 | 1,447.98 | 1,511.64 |
| | 1,601.22 | 2,043.83 | 1,414.61 | 1,496.35 |
| | 76.89% | 82.63% | 97.69% | 98.99% |
| | 61.00% | 56.06% | 69.84% | 70.50% |

2023 3 28

98.99%

97.69% 82.63% 76.89%

2022 9

2019

2020

70.50% 69.84% 56.06%

61.00%

2022

| | | | | | | |
|--------|------|------|------|------|------|------|
| | | | | | | |
| 2022Q1 | 0.83 | 0.30 | 3.78 | 8.76 | 1.08 | 0.62 |
| 2022Q2 | 0.85 | 0.29 | 3.88 | 7.89 | 1.13 | 0.62 |
| 2022Q3 | 0.85 | 0.25 | 3.92 | 8.91 | 1.00 | 0.62 |
| 2022Q4 | 0.85 | 0.28 | 4.12 | 8.02 | 0.91 | 0.59 |

| | % | | | |
|--|-------------|-------------|-------------|-------------|
| | 2022.9.30 | 2021.12.31 | 2020.12.31 | 2019.12.31 |
| | 0.51 | 0.62 | 0.68 | 0.10 |
| | 3.46 | 3.95 | 5.11 | 4.22 |
| | 3.05 | 1.77 | 1.94 | - |
| | 1.76 | 1.22 | 1.18 | 1.19 |
| | 0.35 | 0.12 | - | - |
| | - | - | - | - |
| | 1.52 | 1.28 | 1.49 | 0.92 |
| | 1.38 | 2.25 | 0.26 | 0.73 |

2022 9
2022
Wind

3%

2%

1

2

1

3

4

2021

2021

214.67 915.52 2,454.19
1,561.54 2021 1,538.67
2021 2020

| | 2021 | | 2020 | |
|--|-----------------|----------------|---------------|----------------|
| | 1,720.73 | 70.11% | 404.38 | 44.17% |
| | 733.46 | 29.89% | 511.14 | 55.83% |
| | 2,454.19 | 100.00% | 915.52 | 100.00% |

2021 2021 1,316.35
2021 2021

222.32

9

7

1

16

12

24

2019 9

25

| | 2022 1-9 | 2021 | 2020 | 2019 |
|--|-----------------|-------------|-------------|-------------|
| | 26,698.68 | 31,383.82 | 28,167.67 | 5,404.48 |

| | 2022.9.30 | 2021.12.31 | 2020.12.31 | 2019.12.31 |
|--|------------------|-------------------|-------------------|-------------------|
| | 1,561.54 | 2,454.19 | 915.52 | 230.41 |
| | 919.34 | 2,375.92 | 915.52 | 230.41 |
| | 58.87% | 96.81% | 100.00% | 100.00% |

2023 3 28

2019 2020 2021

100.00% 100.00% 96.81% 2021

2022 9

2021



27

1

2

3

18

7

1

1-28

1

2

3

4

5

6

2

2022 9 30

| | | | | |
|---|--|-----------|--|--|
| | | | | |
| 1 | | 262.60 | | |
| 2 | | 2,541.03 | | |
| 3 | | 15,600.53 | | |
| 4 | | 4,889.78 | | |

| | | | |
|---------|------|---|----------|
| 2 | | | |
| | 2017 | 3 | 8,000 |
| | | | 5 |
| 0.0625% | | | 4,000 |
| | | | 50% |
| 2020 | | | |
| 3,995 | | | 49.9375% |
| | | | |
| | | | 8 |

4

截至 2022 年 9 月 30 日，公司其他非流动资产账面价值为 4,889.78 万元，主要为预付工程设备款、房屋及土地款、纳税履约保证金等，不属于财务性投资。

综上所述，最近一期末公司不存在持有金额较大的财务性投资（包括类金融业务）情形。

2023 1 5

1 1 5 1 2 5 6

~~8,163.72~~ ~~1,258.49~~ ~~1,652.86~~ ~~3,416.40~~

2021 2022 1-9

5,321.34 4,747.18 6,898.95 12,014.95

2020

2021 2022 1-9 1,246.16 2,667.73
5,602.83

2 2

3 6

1

2

3

4

5

6

7

8

18

7

9

10

11

1

2

4 2022 1-9

GST-HG171

5

6

1

7 2021

8

9

2

94,800.00

74,800

20,000

6

GST-HG121

GST-HG141

GST-HG171

II/III

GST-HG171

70,300.00

74.16%

1

2

3

GST-HG171

4

5

6

7
18
8 9
2 3 8
1 2 6 7 8
9 4 5

1

2023

| | | | |
|----------|------------------|------------------|------------------|
| | | | |
| 1 | | 82,080.00 | 74,800.00 |
| 1-1 | GST-HG171 II/III | 23,460.00 | 20,700.00 |
| 1-2 | GST-HG141 II/III | 29,070.00 | 24,550.00 |

| | | | |
|----------|------------------|-------------------|------------------|
| | | | |
| 1-3 | GST-HG121 II/III | 29,550.00 | 29,550.00 |
| 2 | | 20,000.00 | 20,000.00 |
| | | 102,080.00 | 94,800.00 |

GST-HG171 II/III

II/III

158.00

CRO

GST-HG141 II/III

II

2023

2

513.15

CRO

GST-HG121

II/III

2

671.15

1

2

3

CRO

CRO

CRO

1

2

GST-HG141 GST-HG121 GST-HG171
II/III
I
II
III
GST-HG171 2022 12 GST-HG171 I
GST-HG171 150mg
I
II/III
GST-HG171 Ritonavir /

II/III

CDE
CDE

GST-HG171 GST-HG141

II/III

I

I

GST-HG121

GST-HG171 GST-HG141

GST-HG121 II/III

1

94,800.00

GST-HG171

/

GST-HG141 GST-HG121

| 1 | | 82,080.00 | 74,800.00 | 78.90% |
|----------|---------------------|------------------|------------------|---------------|
| 1-1 | GST-HG171 II/III | 23,460.00 | 20,700.00 | 21.84% |
| 1-2 | GST-HG141 II/III | 29,070.00 | 24,550.00 | 25.90% |
| 1-3 | GST-HG121 II/III | 29,550.00 | 29,550.00 | 31.17% |
| 2 | | 20,000.00 | 20,000.00 | 21.10% |

| | | | |
|--|--|-------------------|------------------|
| | | | |
| | | 102,080.00 | 94,800.00 |
| | | | 100.00% |

2

1

GST-HG171 GST-HG141

GST-HG121

II/III

| | GST-HG171 II/III | GST-HG141 II/III | GST-HG121 II/III | |
|--|-----------------------------|-----------------------------|-----------------------------|---|
| | 16,020.00 | 22,620.00 | 23,050.00 | |
| | 3,480.00 | 3,550.00 | 3,500.00 | |
| | 2,160.00 | 1,500.00 | 1,600.00 | |
| | 1,800.00 | 1,400.00 | 1,400.00 | |
| | 23,460.00 | 29,070.00 | 29,550.00 | - |

II III

1

2 /

/1

2

1

| | | 2023 | | | | 2024 | | | | 2025 | | | | 2026 | | | | 2027 | |
|---------------|--------|------|----|----|----|------|--------|----|----|------|------|----|----|------|----|----|----|------|----|
| | | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 |
| GST-HG17 1 | II/III | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| GST-HG14 1 | II | | | | | | | | | | | | | | | | | | |
| | III | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| GST-HG12 1 | II | | | | | | | | | | | | | | | | | | |
| | III | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| GST-HG171 | | 2023 | | | | 7 | II/III | | | | 2023 | | | | 9 | | | | |

2

2023 3 22

2022

CEO

George Zhang

Wyeth

The Procter & Gamble Company

Allergan

Corbus Pharmaceuticals Holdings, Inc.

John Wei-Zhong Mao

25

18 INDs

2 NDAs Foresee Pharmaceuticals Cytokinetics Idenix Pharmaceuticals

2

1

2022 12

2022 12 22


694

2022

2022

Weekly confirmed COVID-19 cases per million people

Our World in Data



2022

2023 1 30

WHO



| | | | | | | | |
|------------|-----|------|---------|----------|-------|--------------|-------|
| 2023 | 2 | | | | | 2022 | |
| | | | | Paxlovid | | 2022 | 189 |
| | | | | | | Molnupiravir | |
| Lagevrio | 57 | | | | | | |
| Remdesivir | | | Veklury | 39 | | | |
| | | | | 285 | | | |
| | | 2023 | -2026 | | | 2022 | 12% |
| 2026 | 22% | | | 2022 | 1,400 | 2026 | 2,600 |

2


HBV

| | | | | | |
|--|-----|--|--|-------|------|
| | | | | | 2022 |
| | | | | 2017 | |
| | 100 | | | 7,000 | |
| | | | | 15% | |

Frost & Sullivan

| | | | |
|------|--|-------|-----------|
| 2030 | | 723.3 | 2025-2030 |
|------|--|-------|-----------|

35.8%



Frost & Sullivan

3

2 /

/2

/ 1

2 /

/2 / 1

1

1

2021

2

3CL

Mpro

GST-HG171

3CL

16

RNA

3CL

3CL

3CL

3CL

3CL

GST-HG171

GST-HG121

GST-HG141

HBsAg

GST-HG121

First-in-class

RNA

HBsAg

GST-HG121

HBsAg

GST-HG141

HBV

cccDNA

GST-HG141

3

2015 IPO

PCT

4

2 /

/1

2

1


2019

RNA

Daily new confirmed COVID-19 cases per million people

Our World in Data

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.




CC BY Source: WHO COVID-19 Dashboard

<https://ourworldindata.org/coronavirus#explore-the-global-situation>

Nextstrain

2022 5

BA.4/BA.5



Nextstrain

+



HBV

2022

2017

100

7,000

15%

2022

HBsAg

HBV DNA

0%-3%

GST-HG121

GST-HG141

3

GST-HG121

1
II/III

GST-HG171 GST-HG141

I IIT

2

3

2022

4

2

1

GST-HG171

IC₅₀

IC₅₀

50%

IC₅₀

GST-HG171

GST-HG171

BA.4 BA.5

IC₅₀ EC₅₀

Nirmatrelvir

/PF-07321332

Paxlovid

IC₅₀

GST-HG171

6.6

IC₅₀

GST-HG171 10

B.1 BA.4

BA.5 IC₅₀

GST-HG171

8.7

2.4

5.0

GST-HG171

Paxlovid

| | IC ₅₀ | | | | |
|-------------|------------------|-------|-------------|--------------|--------------|
| | | Delta | Omicron B.1 | Omicron BA.4 | Omicron BA.5 |
| GST-HG171 | 0.079 | 0.049 | 0.048 | 0.049 | 0.070 |
| PF-07321332 | 0.522 | 0.492 | 0.418 | 0.120 | 0.351 |

PF-07321332/Nirmatrelvir

Paxlovid

2

GST-HG171

1,189.23 700.72 472.80
 509.67 328.74 236.06 GST-HG171

| | ORF1ab | | N | | S | |
|-------------|----------|----------|----------|----------|----------|----------|
| | 150mg/kg | 450mg/kg | 150mg/kg | 450mg/kg | 150mg/kg | 450mg/kg |
| GST-HG171 | 1,427.80 | 1,189.23 | 2,425.53 | 700.72 | 485.75 | 472.80 |
| PF-07321332 | 29.06 | 509.67 | 20.10 | 328.74 | 22.69 | 236.06 |

GST-HG171

BA.4 BA.5

GST-HG171 II/III

II/III

GST-HG171

2

/

/2

RNA

VOC

BA.2.75 BA.5

1

GST-HG171

1

2

2 /

/1

2

2023 2

2022

Paxlovid 2022 189

Molnupiravir

Lagevrio 57

Remdesivir Veklury 39

285

2023 -2026

2022 12%

2026 22% 2022 1,400 2026 2,600

3

S

RBD

2 ACE2

RBD

ACE2 S

FP

Mpro

16

RNA

RNA

3CL
 RdRp RNA Paxlovid
 Molnupiravir 3CL RdRp
 RdRp 3CL
 3CL S
 3CL 3CL X
 3CL
 3CL

| | | | |
|-----------|--------|--|--------|
| | | | |
| Paxlovid | | | |
| S-217622 | | | |
| SIM0417 | | | |
| RAY1216 | | | |
| GST-HG171 | | | II/III |
| PBI0451 | Pardes | | II |
| QLS1128 | | | II |
| GS221 | | | II |
| SYH2055 | | | I |
| ASC11 | | | I |
| HS-10517 | | | I |

RdRp VV116
 RdRp
 1
 GST-HG171
 II/III 2
 I IIT Paxlovid
 Paxlovid
 3 GST-HG171
 GST-HG171

150mg

Paxlovid

300mg

RAY1216

400mg

SIM0417

750mg

GST-HG171

I

2023 3 23

2023

A

2021

2023 3 22

2023

A

2021

1

2

3

GST-HG171 GST-HG141

GST-HG121

GST-HG171 2022 9 23

GST-HG141 2019 11 5

GST-HG121

2020 8 26 2020 9 4

4

2019

1

2020 10

2021

| | | | % |
|---|--|------------------|---------------|
| 1 | | 31,500.00 | 81.08 |
| 2 | | 1,750.00 | 4.50 |
| 3 | | 1,750.00 | 4.50 |
| 4 | | 1,400.00 | 3.60 |
| 5 | | 1,400.00 | 3.60 |
| 6 | | 875.00 | 2.25 |
| 7 | | 175.00 | 0.45 |
| | | 38,850.00 | 100.00 |

6

5%

| | | | | | % |
|--|--|-----------------------|--|-----|-------|
| | | John Wei-Zhong Mao | | 210 | 12.00 |
| | | | | 151 | 8.63 |
| | | | | 137 | 7.83 |
| | | | | 200 | 11.43 |
| | | | | 165 | 9.43 |
| | | | | 10 | 0.57 |
| | | | | 40 | 2.29 |

5%

1

81.0811%

2

3

6

1

2

2

| | |
|--|--|
| | |
| | |
| | |

| | |
|--|--|
| | |
| | |
| | |
| | |
| | |

3

| | | |
|--------|---------------|--------|
| | | |
| 002653 | III II/III | II/III |
| 300204 | | |

| | |
|--------|--|
| 002294 | |
| 002603 | |
| 300158 | |

II/III

| | 2022 1-9 | 2021 | 2020 | 2019 |
|------|-----------------|-------------|-------------|-------------|
| | 12,125.60 | 7,342.71 | 5,913.99 | 7,004.78 |
| | 110.64 | 443.77 | 1,166.80 | 1,683.44 |
| | 0.91% | 6.04% | 19.73% | 24.03% |
| 2021 | | | | 726.34 |

2021

5

5

53.19%

1

| | | | | |
|-----------|-----|-----------------|----------|-----|
| | | | | |
| GST-HG171 | | 2021.12-2022.09 | 5,685.38 | |
| | IND | 2022 9 23 | | |
| | I | 2022.10-2022.12 | | |
| GST-HG141 | | 2016.06-2019.08 | 4,935.93 | III |
| | IND | 2019 11 5 | | |
| | I | 2020.05-2022.07 | | |
| GST-HG121 | | 2019.03-2020.06 | 2,508.75 | III |
| | IND | 2020 8 26 9 4 | | |

2

2

2

GST-HG171

I

IIT

GST-HG171



| | 2021 | 2020 | 2019 |
|--|---------------|---------------|---------------|
| | 0.81% | 2.62% | 3.04% |
| | 42.19% | 32.72% | 32.55% |
| | 51.23% | 41.69% | 17.52% |
| | 42.63% | 42.71% | 41.92% |
| | 44.52% | 32.76% | 34.25% |
| | 70.08% | 80.47% | 73.69% |
| | 10.86% | 25.90% | 24.03% |
| | 29.04% | 36.03% | 31.31% |
| | 15.00% | 32.48% | 9.82% |
| | 14.78% | 17.79% | 14.59% |
| | 48.32% | 51.95% | 26.30% |
| | 5.46% | 11.20% | 24.13% |
| | 15.25% | 25.49% | 18.97% |
| | 31.55% | 34.51% | 29.42% |
| | 6.04% | 19.73% | 24.03% |

1

2022

2

2021

2

A

| | | | | | |
|--|----------------------|------------------|-----------|-----------|---------------|
| | | | | | |
| | KW-027 | I/II/III | 21,700.00 | 15,000.00 | 69.12% |
| | STSA1002 STSA1005 | II/III | 29,400.00 | 25,200.00 | 85.71% |
| | SAL007 | HER3 I/II/III | 35,920.44 | 32,776.44 | 91.25% |
| | SAL0951 | I/III | 67,272.03 | 66,657.31 | 99.09% |
| | S086 | II/III / | 61,094.46 | 59,411.91 | 95.97% |
| | | | | | 88.23% |
| | GST-HG171 | II/III | 23,460.00 | 21,505.00 | 91.67% |
| | GST-HG141 | II/III | 29,070.00 | 24,550.00 | 84.45% |
| | GST-HG121 | II/III | 29,550.00 | 25,050.00 | 84.77% |
| | | | | | 86.96% |

II/III

3

5

5

53.19%

II/III

86.96%

1

18

本次向特定对象发行股票募集资金用于“创新药研发项目”与“补充流动资金项目”，其中创新药研发项目中拟投向的研发药物均为一类新药，拟使用的募集资金均用于项目的临床 II 期或 III 期。依据公司的研发资本化原则，公司按照下列方法确定内部研究开发支出的资本化时点：

| | |
|--|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

依据上述资本化原则，公司本次募投项目的资本化投入情况如下所示：

单位：万元 TW5Har56L@15

| | | | | |
|-----------|--------|-------------------|------------------|---|
| | | | | |
| GST-HG171 | II/III | 23,460.00 | 20,700.00 | |
| GST-HG141 | II | 4,520.00 | - | - |
| | III | 24,550.00 | 24,550.00 | |
| GST-HG121 | II | 4,500.00 | 4,500.00 | |
| | III | 25,050.00 | 25,050.00 | |
| | | 20,000.00 | 20,000.00 | |
| | | 102,080.00 | 94,800.00 | - |

21,505.00

1,955

10

| | | | |
|--|--|---|------|
| | | | |
| | | | 10 |
| | | X | |
| | | | 10 |
| | | | 15 |
| | | | 10 |
| | | | |
| | | | 8-20 |
| | | | 17 |

| | 2023 年 | 2024 年 | 2025 年 | 2026 年 | 2027 年 | 2028 年 | 2029 年 | 2030 年 |
|-----------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| GST-HG171 | 716.83 | 2,150.50 | 2,150.50 | 2,150.50 | 2,150.50 | 2,150.50 | 2,150.50 | 2,150.50 |
| GST-HG141 | - | - | 204.58 | 2,455.00 | 2,455.00 | 2,455.00 | 2,455.00 | 2,455.00 |
| GST-HG121 | - | - | - | - | 1,670.00 | 2,505.00 | 2,505.00 | 2,505.00 |
| | 716.83 | 2,150.50 | 2,355.08 | 4,605.50 | 6,275.50 | 7,110.50 | 7,110.50 | 7,110.50 |
| | 2031 年 | 2032 年 | 2033 年 | 2034 年 | 2035 年 | 2036 年 | 2037 年 | 2038 |
| GST-HG171 | 2,150.50 | 2,150.50 | 1,433.67 | - | - | - | - | - |
| GST-HG141 | 2,455.00 | 2,455.00 | 2,455.00 | 2,455.00 | 2,250.42 | - | - | - |

| | | | | | | | | | |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|---|
| GST-HG121 | 2,505.00 | 2,505.00 | 2,505.00 | 2,505.00 | 2,505.00 | 2,505.00 | 2,505.00 | 835.00 | - |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|---|

| | | | |
|---|-----------|------------|-----------|
| | | [2020]2748 | 2021 |
| 6 | | 1,877.70 | 27.40 |
| | 51,448.98 | | 49,958.41 |
| | 2022 9 30 | | 35,948.88 |
| | 71.96% | 14,550.20 | |

2022 9 30

| | | | |
|--------|-------|-------|-----------|
| | | | |
| | | = / | 16,409.94 |
| 2021 | | = + - | 39,438.88 |
| 2021 | | | 13,834.55 |
| 2021 | | | 30,890.45 |
| 2021 | | | 5,286.11 |
| | =360÷ | | 2.40 |
| | | = + - | 149.79 |
| | | | 177.62 |
| | | | 51.21 |
| | | | 79.04 |
| 2022 9 | | | 29,985.32 |
| | | | 14,550.20 |
| 2022 9 | | | 15,435.12 |
| | | | 16,409.94 |

| | |
|---|------------------|
| | |
| | |
| + | 25,562.26 |
| + | 26,537.08 |

2022 9 30

16,409.94

26,537.08

20,000.00

2 3 8

1 2

==

=====

==

2

3

3

8

3

4

5

6

7

2021

8

2023

A

2023

A

9

GST-HG171

GST-HG141

GST-HG121

10

11

2023

A

12

13

14

2022

15

16

17

18

18

1

1

2



3 GST-HG171

GST-HG171

4

5

6

7

30%

18

8

716.83

-7,110.50

9

20,000.00

2

1

2

3

4

30%

18

5

716.83

-7,110.50

6

20,000.00

3

1

2

3

2019 5

31

10

18

| | | | | | | |
|---|---------------|--|--|---------|------------|--|
| | | | | | | |
| 1 | 2019 5 31 | | | 100,000 | 2019 32 | |
| 2 | 2019 11 22 | | | 20,000 | 2019 90008 | |

100,000

2

2019 11 22 2017 12 2018 11

[2019]90008

20,000

3

2022 4 19 2022 2 1 2022 2 28

[2022]58

50

2022 7 20 2022 6 1 2022
6 30

[2022]208

50

2022 9 20 2022 7 1 2022
7 31

[2022]222

50

<

>

18

1

2

3

1

2019 8 19

2019 6 19

2019 8 16

100,000

2020 2 28

2016

2023 3 23

1-92

2

2019 11 25

20,000

2020 2 20

3

2022 4 19

2022

7 21 2022 9 20

50

1

2

3

4

5



4

2022 9

35,068,651

22.02%

23,110,000

65.90%

21,610,000

61.62%

26,790,000

35.87%

16.82%

| | | | | | | % | % | % |
|--|------------|--------|-----------|--|--|-------|------|-------|
| | 2022.08.03 | 13,000 | 9,210,000 | | | 26.26 | 5.78 | 12.33 |
| | 2022.09.14 | 10,000 | 6,900,000 | | | 19.68 | 4.33 | 9.24 |

| | | | | | | | | |
|--|------------|-------|-------------------|---|---|--------------|--------------|--------------|
| | | | | | | | | |
| | 2023.03.06 | 8,500 | 5,000,000 | | | 14.26 | 3.14 | 6.69 |
| | 2023.03.23 | | 500,000 | | | 1.43 | 0.31 | 0.67 |
| | 2022.04.29 | 5,000 | 5,180,000 | | | - | 3.25 | 6.94 |
| | | | 26,790,000 | - | - | 61.62 | 16.82 | 35.87 |

2022 9 30

| | | | | | | |
|---|------------|------------|-----------|--------|--|--|
| | | | | | | |
| 1 | 2021.02.26 | 2023.03.02 | 3,000,000 | 10,000 | | |
| 2 | 2021.09.14 | 2023.03.03 | 4,000,000 | | | |

300436.SZ

30%

1270

bitc2022(or)-2059

15%

50%

1
/

60 >50%

3 5

/ +

<50%

13.

13.1

13.1.1

13.1.2 / /

13.1.3

13.1.4

13.1.5

13.1.6

1

2022 9 30

| | | |
|------------|-----------|-----------|
| 181,235.44 | 93,559.12 | 53,562.56 |
| 32,969.62 | | 29.55% |

2

| | | | | % | % | / | / |
|---|--|-----|--------|-----|-----|-------|-------|
| 1 | | 921 | 13,000 | 160 | 150 | 22.58 | 21.17 |
| 2 | | 690 | 10,000 | 160 | 150 | 23.19 | 21.74 |
| 3 | | 500 | 8,500 | 200 | | 30.91 | |
| | | 50 | | | | | |

2023 4 3 32.82 2023 4 3
 20 60 120 33.64
 39.53 42.31

3

21,610,000
 61.62%
 26,790,000
 74,691,217
 35.87%
 2023 3 31

15 6

1,592,670

1%

1,592,670

36.65%

4

/ /
/ /

/ / /

/ /

7,469.12



1

2

3

300

400

4

5

2022

6

7

8



2023 3 3

| | | | | |
|---|------------|--|--|--|
| | | | | |
| 1 | 2023.03.14 | | | |
| 2 | 2023.03.17 | | | |
| 3 | 2023.03.17 | | | |
| 4 | 2023.04.04 | | | |

1

1

2

（本页无正文，为福建广生堂药业股份有限公司《关于福建广生堂药业股份有限公司申请向特定对象发行股票的审核问询函的回复》之盖章页）



(本页无正文，为兴业证券股份有限公司《关于福建广生堂药业股份有限公司申
请向特定对象发行股票的审核问询函的回复》之签章页)

保荐代表人：



吴文杰



周 倩



兴业证券股份有限公司

2023年4月6日

保荐机构董事长、法定代表人声明

本人已认真阅读福建广生堂药业股份有限公司本次审核问询函回复报告的全部内容，了解报告涉及问题的核查过程、本公司的内核和风险控制流程，确认本公司按照勤勉尽责原则履行核查程序，本回复不存在虚假记载、误导性陈述或者重大遗漏，并对上述文件的真实性、准确性、完整性、及时性承担相应法律责任。

保荐机构董事长、法定代表人：


杨华辉



兴业证券股份有限公司

2022年9月20日

2022年9月20日